Healthpeak Properties DOC
Real Estate · REIT - Healthcare Facilities · Synthos Deep Dive · 2026-07-03
The Overview
Healthpeak is a landlord — it owns and rents out medical buildings: doctors' offices, lab/research space for drug companies, and senior-housing communities. Tenants pay rent, and Healthpeak passes most of the cash to shareholders as a monthly dividend that works out to about 5.6% a year. That is the whole appeal: a steady rent check, not a fast-growing business.
Is the stock cheap or expensive? About fairly priced — maybe a touch expensive. It has climbed 22% in the past year and now trades a little above what Wall Street analysts think it's worth. So the easy money may already be made.
Our verdict is Watch: a fine choice if what you want is income, but not a bargain and not a grower today.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit above average). It owns real buildings and the stock doesn't swing wildly, but it carries a lot of debt, and REITs like this fall when interest rates rise.
- Growth Quality 4/10 (below average). Rents grow slowly. Same-store income was flat this quarter. This is a plow-horse, not a race-horse.
- Exponential Potential 2/10 (low). A mid-size landlord in a mature market — there is no path here to doubling quickly.
The one big worry: it borrows a lot (debt is about 5.3× its yearly cash earnings), so if interest rates rise or refinancing gets expensive, both the stock and the dividend safety get squeezed.
Putting a number on it: our fair-value estimate is $21 against a current price of $20.96 — real upside if our numbers are right.
Our summary metrics
5.3× net-debt/EBITDA and rate sensitivity offset a low-beta, hard-asset base; trades slightly above street targets.
Low-single-digit FFO/rev growth, flat same-store NOI (0.0%), high but stable margins — a steady REIT, not a grower.
Landlord economics + a ~$15B cap in a mature TAM; no acceleration. Structurally not an exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Landlord economics + a ~$15B cap in a mature TAM; no acceleration. Structurally not an exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $19.71 (high $24 / low $17; 22 Buy · 19 Hold · 0 Sell) — context, not our anchor; note it sits below today's price |
| Valuation | ~12× P/FFO (FFO-adj run-rate ~$1.80) · EV/EBITDA 13.8× · P/B 1.9× · dividend yield 5.6% |
| Technicals | Uptrend — $21.89 at the 52-wk high, above 50/200-DMA, RSI 64, +22% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices, 0 traceable KB claims; call rests on fundamentals + quant only |
| Position sizing | If owned, an income sleeve holding (~1–3%), not a growth position |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for DOC — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $20.96, 3% below the 50-day average ($21), 13% above the 200-day average ($19) — a mixed trend. 8% below the 52-week high of $23, 33% above the 52-week low of $16.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $20.96 is currently inside the band (band $20–$22).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 45.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.03, positive momentum.
Relative performance vs S&P 500 & its sector (XLRE (sector)), set to 100 a year ago
Solid = DOC · dashed = S&P 500 · dotted = XLRE (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Healthpeak Properties (NYSE: DOC) is an S&P 500, fully-integrated healthcare real estate investment trust (REIT) headquartered in Denver, formed in its current shape by the 2024 merger of Healthpeak and Physicians Realty Trust (the ticker "DOC" is inherited from the latter). It owns, operates and develops real estate for healthcare discovery and delivery. Fiscal year ends December 31. The REIT structure means it pays out most of its taxable income as dividends and is best judged on FFO (funds from operations), not GAAP EPS — GAAP net income is depressed by heavy real-estate depreciation ($1.06B in FY25 vs $2.82B revenue).
Revenue mix (FY2025, from segment filings — total $2.74B of segment revenue):
- Outpatient Medical Buildings — $1.27B (46%): the core, stickiest segment; +2.4% same-store NOI in Q1'26 with +5.4% cash releasing spreads on renewals.
- Lab — $860M (31%): life-science research space; the softest segment right now (−7.2% same-store NOI in Q1'26) amid biotech-tenant demand weakness, though management says occupancy is expected to rise through year-end.
- Senior Housing — $604M (22%): the growth pocket (+13.8% same-store NOI in Q1'26); now largely housed in Janus Living (NYSE: JAN), a senior-housing entity Healthpeak IPO'd in March 2026 and still owns ~81.6% of.
2. The expert thesis (traceability)
There is no expert coverage of DOC in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top array is empty. No independent voice in our panel has published a traceable claim on this name.
Per house standard, we say this plainly: the verdict here is fundamentals- and quant-driven, not conviction-driven. There are zero claim_id values to cite because none exist. Readers should weight this note accordingly — it reflects the data (financials, estimates, valuation, technicals) and our scenario model, and carries none of the multi-voice expert corroboration that a conviction-track name like LLY does. Absence of coverage is itself a (mild) signal: DOC is a slow-compounding income REIT that the alpha-oriented voices in our panel simply do not discuss.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Hard-asset base and beta ~1.0 are steadying, but net-debt/EBITDA 5.3× is real leverage, REITs are rate-sensitive, and the stock trades above Street targets after +22%. Max historical drawdown from peak was −41%. |
| Growth Quality | 4 · Below Average | Revenue CAGR only ~5% to FY29E; total same-store NOI 0.0% in Q1'26 (Lab −7.2% offset gains); EBITDA margin high (~62%) but flat; ROIC modest. A steady REIT, not a compounder. |
| Exponential Potential | 2 · Low | Landlord economics + a mature TAM + no acceleration. Structurally cannot 2–3× on fundamentals. The Janus Living senior-housing angle is the only real optionality, and it's incremental. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities. For a REIT we anchor value on P/FFO (FFO-as-adjusted run-rate ~$1.80/share, annualizing the $0.45 Q1'26 print), cross-checked against dividend yield.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Lab occupancy recovers, senior-housing (Janus) momentum continues, rates fall and cap rates compress; FFO grows to ~$1.90 and the multiple re-rates to ~13.5× P/FFO. | ~$26 (+19%) |
| Base (our anchor) | FFO-adjusted ~$1.80–1.85; steady outpatient-medical core, Lab stabilizes; a fair ~11.5–12× P/FFO for a low-growth, moderately-levered healthcare REIT. | ~$21 (−4%) |
| Bear | Lab weakness deepens, rates rise / refinancing bites the 5.3× levered balance sheet, cap rates expand; FFO slips and the multiple de-rates to ~9×. | ~$16 (−27%) |
Synthos fair value = the base case, ~$21 (−4%), with the full $16–$26 span as the honest range. Our base sits above the Street's $19.71 consensus (we give slight credit to the senior-housing growth and covered yield) but note that even the Street's target implies modest downside from today's $21.89 — the stock has run to the top of its reasonable range. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). DOC is neither — it is a mature income REIT, and we score it honestly:
- Forward growth: revenue CAGR FY25→FY29E ~6.8% ($2.82B → $3.67B on consensus), but the base years are lower — FY26E $2.95B is only +4.4% on FY25. FFO-per-share growth is low-single-digit.
- Acceleration (2nd derivative): essentially flat/none. Total same-store NOI grew 0.0% in Q1'26 (Senior Housing +13.8% and Outpatient +2.4% exactly offset by Lab −7.2%). There is no inflection to ride.
- Room to run: at $15.1B the cap is mid-size, but the healthcare-real-estate TAM is mature and DOC grows it by acquiring buildings and raising rents at low-single-digit spreads — not by scaling a product. The law of large numbers is not the binding constraint here; the business model is.
- Optionality: the one genuine lever is Janus Living — the senior-housing IPO (Healthpeak owns ~81.6%) that raised ~$880M for accretive senior-housing M&A into favorable supply/demand fundamentals. Real, but incremental, not exponential.
Exponential Potential: Low (2/10). Own DOC for a covered ~5.6% yield and hard-asset stability, not for capital appreciation. Rating it anything higher would be dishonest.
5. Financials (real numbers — FMP annual/quarterly; FFO from the 8-K)
- Revenue: FY25 $2.82B, +4.5% (FY24 $2.70B, +23.8% on FY23 $2.18B — the FY24 jump is the Physicians Realty merger, not organic). Organic growth is low-single-digit.
- FFO (the metric that matters for a REIT): Q1'26 Nareit FFO $0.42/sh, FFO-as-adjusted $0.45/sh (per the 8-K). Annualized run-rate ≈ $1.80 FFO-adjusted — this, not the $0.10 GAAP EPS, is the real cash-earnings figure.
- GAAP EPS is misleadingly low: FY25 EPS $0.10 (net income $71M) because $1.06B of real-estate depreciation runs through the P&L. Q1'26 GAAP EPS was $0.28 (helped by a JV gain). Do not value this REIT on GAAP P/E (69× TTM is meaningless here).
- Margins: EBITDA margin ~62% TTM — high and stable, characteristic of a rent-collecting landlord. Operating margin ~18%.
- Cash flow: operating & free cash flow ~$1.25B FY25 (REITs have low maintenance capex), comfortably funding the $849M of common dividends paid — dividend is covered by cash flow (FCF/dividend ~1.5×) even though the GAAP payout ratio looks alarming (>300%) because GAAP net income is depression by depreciation.
- Balance sheet: total debt $10.4B, net debt $9.9B, net-debt/EBITDA 5.3× (5.4× on the company's Adjusted EBITDAre) — typical-to-slightly-elevated for a REIT, and the core risk vector. Interest coverage a thin ~1.6×. Cash $538M, current ratio 2.0×.
6. Valuation — priced in or room?
Value a REIT on FFO and yield, not P/E. On the ~$1.80 FFO-adjusted run-rate, DOC trades at ~12.2× P/FFO — a reasonable-to-slightly-full multiple for a low-growth healthcare REIT (peers span roughly 10–15×). EV/EBITDA is 13.8× and P/B 1.9×. The 5.6% dividend yield is the real draw and is cash-covered. The tell on the equity side: after a +22% twelve months the stock at $21.89 sits above the Street's $19.71 consensus target (median $19, high $24, low $17) — i.e. analysts, on balance, see the stock as slightly ahead of fair value. FMP's own letter grade is C+ (overall score 2/5; P/E and debt-to-equity flagged weakest). Read: fairly-to-fully valued. Not expensive enough to short, not cheap enough to chase — the definition of a Watch. A better entry would be a pullback toward the mid-$18s (below the Street target, ~14× P/FFO-normalized and a ~6.5% yield).
7. Technicals (from the tech block)
- Trend: up. $21.89 sits above the 50-DMA ($19.31) and 200-DMA ($17.90), and the 50 is above the 200 (golden-cross posture). MACD +0.66 (positive).
- Location: exactly at the 52-week high ($21.89), +38.7% off the 52-week low ($15.78) — a name pushing new highs. Note the longer-term scar: max drawdown from prior peak was −41%, a reminder of how far rate-driven REIT selloffs can go.
- Momentum: RSI(14) 64 — strong but not yet overbought (<70); pushing new highs argues for patience on entry rather than chasing.
- Relative strength: DOC +22.4% 12-mo vs SPY +20.6% (roughly in line) but +33.6% 3-mo vs SPY +13.7% — recent outperformance has been sharp, consistent with a rate-relief/income-rotation move. It has lagged QQQ (+30.3% 12-mo).
- Read: technicals are constructive but the stock is at highs and above analyst targets — momentum is good, valuation is not. No technical urgency to buy here.
8. Moat & competitive position
DOC's "moat" is ordinary REIT economics: irreplaceable locations (outpatient medical buildings physically attached to or adjacent to hospital campuses have high tenant-retention and re-leasing power — the +5.4% renewal spreads show it), scale in a fragmented healthcare-real-estate market, and the stickiness of healthcare tenants. It is not a durable, wide moat in the compounding sense — it is a spread business (borrow, buy buildings, collect rent above the cost of capital) whose returns are capped by cap rates and interest rates. The Lab segment is the soft spot (biotech-tenant demand is cyclical and currently weak); Senior Housing (via Janus Living) is the demographic tailwind.
Peer set (FMP-supplied, market cap): American Healthcare REIT $11.4B and Omega Healthcare $14.7B are the closest healthcare-REIT comps; the rest of the list is cross-sector REITs — BXP $11.1B (office), Regency Centers $14.8B (retail), Equity LifeStyle $12.8B, Gaming & Leisure $12.4B, Lamar $16.0B (billboards), Annaly $16.5B (mortgage REIT), American Homes 4 Rent $12.2B (SFR). Against dedicated healthcare-REIT peers DOC is a large, diversified, investment-grade operator — a quality name within a low-growth category.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and shareholder-friendly this cycle — $100M of buybacks in April 2026 (5.9M shares at $16.81, ~$306M left on a $500M authorization), the Janus Living IPO (~$880M raised for accretive senior-housing M&A), and a JV recapitalization with Blackstone on a six-property outpatient portfolio ($212M valuation, $170M proceeds) that recycles capital while keeping management fees. Monthly dividend of $0.10167 (annualized $1.22). CEO Scott Brinker.
- Insider activity: the sampled Form 4s (filed 2026-06-02) are routine equity-award grants and in-kind tax withholding (A-Award / F-InKind) to directors and officers — normal compensation mechanics, no open-market discretionary buying or selling to read into.
- Management's own guidance (half-weighted, self-interested): the SEC 8-K earnings release (filed 2026-05-05) is a real earnings release and headlines "Healthpeak Properties Raises 2026 Earnings Guidance" following the Janus Living IPO, accretive capital allocation, and a strong Q1. Q1'26 delivered net income $0.28/sh, Nareit FFO $0.42/sh, FFO-as-adjusted $0.45/sh, with year-over-year consolidated revenue and Adjusted EBITDAre growth of 35% and 42% (merger/consolidation-boosted) and net-debt/Adjusted EBITDAre of 5.4×. Note: the specific full-year FFO guidance-range numbers were beyond the truncated portion of the release we ingested; we can confirm management raised guidance and reported the Q1 figures above, but do not fabricate the exact FY26 range. Treat all of this as management's own book, half-weighted.
10. Catalysts & what to watch
- Next earnings: 2026-08-04 (Q2'26; Street EPS $0.02 GAAP, revenue ~$719M). The lines that matter: FFO-as-adjusted per share, same-store NOI by segment (especially whether Lab stops bleeding), and any FY26 FFO guidance update.
- Lab occupancy: management guided occupancy to rise through year-end 2026 — the swing factor for the growth score.
- Janus Living (JAN): execution on the $400M of senior-housing acquisitions under contract; JAN's own results flow into DOC (81.6% owned).
- Rates / refinancing: the dominant macro driver for a 5.3×-levered REIT — cap-rate moves and refi costs on the $10.4B debt stack.
- Dividend: monthly $0.10167; watch coverage and any growth.
Thesis tripwires (what would change the call): Lab same-store NOI worsening for another two quarters; FFO-adjusted guidance cut; net-debt/EBITDA drifting above ~6×; or a dividend-coverage scare. Conversely, a pullback to the mid-$18s with stable FFO would flip this toward Buy — Tactical for income buyers.
11. Key risks
- Interest-rate / cap-rate sensitivity (structural): the biggest driver. Rising rates lift the discount on rent streams, raise refinancing costs on $10.4B of debt, and compress the equity — DOC's −41% peak-to-trough drawdown history shows the magnitude.
- Leverage: net-debt/EBITDA 5.3× with thin ~1.6× interest coverage leaves less cushion than a fortress balance sheet.
- Lab-segment / biotech cyclicality: −7.2% same-store NOI signals real tenant-demand softness in life-science space.
- Valuation: trades above Street targets after a +22% run — limited margin of safety at $21.89.
- No expert corroboration: zero KB coverage means no independent-voice check on this fundamentals-only call — a conviction gap, not a red flag, but worth stating.
- Senior-housing operating risk: operationally intensive (staffing, occupancy, labor costs) vs triple-net leases — Janus concentrates this exposure.
12. Verdict, position sizing & monitoring
Watch. Healthpeak is a genuinely good income REIT — a diversified, investment-grade healthcare landlord with a cash-covered ~5.6% dividend, a sticky outpatient-medical core, and shareholder-friendly capital recycling (Janus IPO, Blackstone JV, buybacks). But it is not a Buy at $21.89: growth is low-single-digit, same-store NOI is flat, the balance sheet is meaningfully levered into a rate-sensitive business, the stock trades above the Street's own price targets after a strong year, and there is no expert conviction in our KB to lean on. The honest rating is Watch — with a clear path to an upgrade on a better price.
- Sizing: for investors who specifically want yield, an income-sleeve position (~1–3%), not a growth or flagship holding. We are not initiating today; we'd want the mid-$18s (a ~6.5% yield and a discount to Street targets) for a Buy — Tactical income entry.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-08-04 print, watching FFO-adjusted, Lab NOI, and any guidance change. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $21.89.
- Single biggest risk: interest-rate / cap-rate sensitivity on a 5.3×-levered balance sheet.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of DOC in the Synthos knowledge base, and no
claim_idvalues exist to cite. This note is explicitly fundamentals- and quant-driven; fabricated conviction is structurally impossible (claim-ID reconciliation) and none is implied here. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · FFO figures from the SEC 8-K earnings release filed 2026-05-05. Forward figures are analyst consensus (FMP), labeled as estimates.
- Management caveat: the FY26 guidance-raise and Q1 FFO figures in §9 are management's own words from the 8-K, half-weighted by design; the exact full-year guidance range was outside the ingested text and is not stated to avoid fabrication.
- REIT note: DOC is valued on FFO and dividend yield, not GAAP EPS — the 69× trailing GAAP P/E is an artifact of real-estate depreciation and is not a meaningful valuation input.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").